search
Back to results

Indocyanine Green for Perfusion Assessment of DIEP Flaps (FAFI)

Primary Purpose

Fat Necrosis

Status
Recruiting
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
Near-infrared fluorescence imaging of perfusion
Sponsored by
Leiden University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Fat Necrosis focused on measuring Fat necrosis, Near-infrared fluorescence imaging, Indocyanine green, Free flap surgery, Breast reconstruction, Perfusion

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Female patients 18 years of age and older
  2. Who underwent a mastectomy for breast cancer or prophylactic due to genetic predisposition
  3. Patients scheduled for elective surgery for autologous breast reconstruction, uni- or bilateral, using DIEP or msTRAM flaps. In case of bilateral breast reconstruction the flaps should be bilateral anastomosed.
  4. Written informed consent

Exclusion Criteria:

  1. Allergy to ICG, iodine or shellfish
  2. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the patient
  3. Impaired renal function defined as eGFR< 50 mL/min/1.73m2 (this can be seen in the standard preoperative lab results)

Sites / Locations

  • Leiden University Medical CenterRecruiting
  • Erasmus Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Interventional study arm

Control arm

Arm Description

Surgery will be performed according to local protocol. Flap viability during adequate hemodynamic conditions is evaluated a standard of care. Then after anastomosis of the flap but before the inset, the second intervention is performed. Intervention: evaluation of the perfusion of the skin and fat with fluorescence imaging using ICG. The flap is marked according to the fluorescence imaging evaluation, and parts without perfusion are resected. The remaining flap is inset to the remaining breast skin.

Surgery will be performed according to local protocol.Flap viability during adequate hemodynamic conditions is evaluated as standard of care. Then after anastomosis of the flap but before the inset, the surgeon will leave the room, the researcher will make a recording of the flap and this will have no consequences for the procedure.

Outcomes

Primary Outcome Measures

Clinical relevant fat necrosis
Clinically relevant fat necrosis is defined as a palpable mass, either painful or not, and with or without aesthetic complaints, and developed within three months after surgery. The following grading system according to Lie et al. is used. Only grade III till IV is classified as clinical relevant fat necrosis. III: Major compromised reconstructive outcome, flap involvement:15-50%, clinical findings: Major contour defects (multiple), surgical management: Debridement/secondary procedure IV: Subtotal poor reconstructive outcome, flap involvement: >50%, clinical findings: Skin defects, inadequate volume, volume loss, surgical management: Second local flap/ re-intervention initial flap

Secondary Outcome Measures

Quantify perfusion of flaps
Based on NIRF recordings and correlate these to the development of fat necrosis.
Registration of re-interventions
necessary to treat fat necrosis, in numbers and percentages
Registration of postoperative complications
in numbers and percentages
Duration of surgery in minutes
Of all surgical procedures included
Percentage extra resected tissue
of initial flap in grams based on perfusion assessment
Personal experience/opinion of surgeon performing surgery with fluorescent imaging using ICG.
After every surgery the NASA TASK Load Index is taken by the surgeon.
Patient satisfaction
using BREAST-Q questionnaire, this is an validated questionnaire that is used in multiple research for measuring patient satisfaction

Full Information

First Posted
August 17, 2022
Last Updated
August 17, 2022
Sponsor
Leiden University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05507710
Brief Title
Indocyanine Green for Perfusion Assessment of DIEP Flaps
Acronym
FAFI
Official Title
Indocyanine Green for Perfusion Assessment of DIEP Flaps: A Dutch Multicenter Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2019 (Actual)
Primary Completion Date
September 1, 2025 (Anticipated)
Study Completion Date
October 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Leiden University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Currently during DIEP flap reconstruction, the perfusion of the flap is assessed by the clinical view of the surgeon. Identification of demarcated ischemic zones of the DIEP flap could be optimized by using fluorescence imaging with indocyanine green (ICG) in order to lower the rate of fat necrosis. This study evaluates whether intraoperative perfusion assessment with ICG fluorescence imaging causes a lower rate of fat necrosis compared to conventional intraoperative clinical evaluation of DIEP flaps.
Detailed Description
Rationale: Autologous breast reconstruction after mastectomy due to cancer or prophylactically due to genetically increased risk is frequently performed. A complication that may occur after a deep inferior epigastric artery (DIEP) reconstruction is the occurrence of fat necrosis in the transplanted flap due to ischemia (reperfusion injury). Identification of deep inferior epigastric artery perforators and identification of demarcated ischemic zones of the DIEP flap can be optimized by using fluorescence imaging with indocyanine green (ICG), as has been demonstrated in previous studies. This could result in less fat necrosis, less partial flap loss, and other complications. A randomized controlled trial would be the best study design to assess the value of ICG in determining the perfusion of DIEP flaps, thereby reducing the occurrence of fat necrosis and other complications. Objective: To determine whether fluorescence imaging using ICG for the assessment of DIEP flap perfusion during surgery decreases the occurrence of fat necrosis compared to standard intraoperative clinical assessment of DIEP flap perfusion. Study design: This is a two-armed randomized controlled trial: interventional arm: evaluation of flap perfusion based on 1) clinical parameters, and 2) fluorescence imaging using ICG conventional arm: evaluation of flap perfusion based on clinical parameters only Study population: Patients scheduled for elective surgery for autologous breast reconstruction, uni- or bilateral, using DIEP or muscle sparing transverse rectus abdominis muscle (msTRAM) flaps. Female patients 18 years of age and older. Intervention (if applicable): evaluation of flap perfusion based on 1) clinical parameters, and 2) fluorescence imaging using ICG Main study parameters/endpoints: Difference in percentage of fat necrosis after autologous breast reconstruction using DIEP flaps between patients in whom fluorescence imaging was used and patients in whom flaps were clinically assessed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fat Necrosis
Keywords
Fat necrosis, Near-infrared fluorescence imaging, Indocyanine green, Free flap surgery, Breast reconstruction, Perfusion

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
This is a two-armed randomized controlled trial: interventional arm: evaluation of flap perfusion based on 1) clinical parameters, and 2) fluorescence imaging using ICG conventional arm: evaluation of flap perfusion based on clinical parameters only
Masking
ParticipantOutcomes Assessor
Masking Description
The participant is blinded for the study arm. A second evaluator of postinterventional fat necrosis is blinded for the study arm.
Allocation
Randomized
Enrollment
280 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Interventional study arm
Arm Type
Active Comparator
Arm Description
Surgery will be performed according to local protocol. Flap viability during adequate hemodynamic conditions is evaluated a standard of care. Then after anastomosis of the flap but before the inset, the second intervention is performed. Intervention: evaluation of the perfusion of the skin and fat with fluorescence imaging using ICG. The flap is marked according to the fluorescence imaging evaluation, and parts without perfusion are resected. The remaining flap is inset to the remaining breast skin.
Arm Title
Control arm
Arm Type
No Intervention
Arm Description
Surgery will be performed according to local protocol.Flap viability during adequate hemodynamic conditions is evaluated as standard of care. Then after anastomosis of the flap but before the inset, the surgeon will leave the room, the researcher will make a recording of the flap and this will have no consequences for the procedure.
Intervention Type
Diagnostic Test
Intervention Name(s)
Near-infrared fluorescence imaging of perfusion
Intervention Description
Imaging with ICG near-infrared fluorescence is performed besides clinical judgement of the DIEP flap for perfusion evaluation. Based on fluorescence imaging, additional malperfused area(s) are resected.
Primary Outcome Measure Information:
Title
Clinical relevant fat necrosis
Description
Clinically relevant fat necrosis is defined as a palpable mass, either painful or not, and with or without aesthetic complaints, and developed within three months after surgery. The following grading system according to Lie et al. is used. Only grade III till IV is classified as clinical relevant fat necrosis. III: Major compromised reconstructive outcome, flap involvement:15-50%, clinical findings: Major contour defects (multiple), surgical management: Debridement/secondary procedure IV: Subtotal poor reconstructive outcome, flap involvement: >50%, clinical findings: Skin defects, inadequate volume, volume loss, surgical management: Second local flap/ re-intervention initial flap
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Quantify perfusion of flaps
Description
Based on NIRF recordings and correlate these to the development of fat necrosis.
Time Frame
3 months
Title
Registration of re-interventions
Description
necessary to treat fat necrosis, in numbers and percentages
Time Frame
3 months
Title
Registration of postoperative complications
Description
in numbers and percentages
Time Frame
3 months
Title
Duration of surgery in minutes
Description
Of all surgical procedures included
Time Frame
1 day
Title
Percentage extra resected tissue
Description
of initial flap in grams based on perfusion assessment
Time Frame
1 day
Title
Personal experience/opinion of surgeon performing surgery with fluorescent imaging using ICG.
Description
After every surgery the NASA TASK Load Index is taken by the surgeon.
Time Frame
1 day
Title
Patient satisfaction
Description
using BREAST-Q questionnaire, this is an validated questionnaire that is used in multiple research for measuring patient satisfaction
Time Frame
3 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female patients 18 years of age and older Who underwent a mastectomy for breast cancer or prophylactic due to genetic predisposition Patients scheduled for elective surgery for autologous breast reconstruction, uni- or bilateral, using DIEP or msTRAM flaps. In case of bilateral breast reconstruction the flaps should be bilateral anastomosed. Written informed consent Exclusion Criteria: Allergy to ICG, iodine or shellfish Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the patient Impaired renal function defined as eGFR< 50 mL/min/1.73m2 (this can be seen in the standard preoperative lab results)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexander L. Vahrmeijer, MD, PhD
Phone
+31 71 526 2309
Email
a.l.vahrmeijer@lumc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Pieter S. Verduijn, MD
Phone
0715296212
Email
P.S.Verduijn@lumc.nl
Facility Information:
Facility Name
Leiden University Medical Center
City
Leiden
ZIP/Postal Code
2333ZA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander L. Vahrmeijer, MD, PhD
Phone
+31 71 526 2309
Email
a.l.vahrmeijer@lumc.nl
First Name & Middle Initial & Last Name & Degree
Pieter S. Verduijn, MD
Phone
+31715296212
Email
p.s.verduijn@lumc.nl
First Name & Middle Initial & Last Name & Degree
Floris P Tange, Bsc
Facility Name
Erasmus Medical Center
City
Rotterdam
ZIP/Postal Code
3015GD
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marc A.M. Mureau, MD, PhD
Phone
+31 614390753
Email
m.mureau@erasmusmc.nl

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Indocyanine Green for Perfusion Assessment of DIEP Flaps

We'll reach out to this number within 24 hrs